Prostate cancer remains the most frequently diagnosed cancer among men in the United States, with metastatic progression marking a formidable clinical challenge. Despite initially effective androgen receptor (AR) targeted hormone therapies, many prostate tumors evolve mechanisms to bypass this dependency, engendering more aggressive and treatment-refractory disease states. The R-spondin (RSPO) family—comprising RSPO1, RSPO2, RSPO3, and RSPO4—serves as key modulators of the Wnt signaling pathway, an essential regulator of cellular proliferation, differentiation, and migration. While Wnt pathway disruption is well-documented in oncogenesis, the distinct roles of individual RSPO proteins in prostate cancer have remained underexplored until now.

Leveraging extensive genomic analyses encompassing thousands of metastatic prostate cancer tumor samples, the researchers revealed that RSPO2 alterations, particularly gene amplifications, occur at a striking frequency exceeding 20%. This rate surpasses not only changes in other RSPO family members but also surpasses prominent cancer genes such as CTNNB1 (encoding β-catenin) and APC which are canonical regulators within the Wnt signaling axis. These RSPO2 amplifications correlated with poor clinical outcomes, heightened tumor mutational burden, and elevated genomic instability, underscoring RSPO2’s pivotal oncogenic contribution in aggressive prostate cancer phenotypes.

Functional assays utilizing prostate cancer cell lines established that RSPO2 overexpression drives increased cellular proliferation and activates epithelial-mesenchymal transition (EMT), a phenotypic switch whereby epithelial cells acquire mesenchymal properties. EMT is intimately linked to enhanced metastatic potential, therapeutic resistance, and poor prognosis in many cancers. Notably, RSPO2 induced upregulation of well-known EMT transcription factors including ZEB1, ZEB2, and TWIST1, which coordinate gene expression programs promoting cell motility and invasiveness. This mechanistic insight frames RSPO2 as an instrumental factor catalyzing tumor progression and dissemination.

Intriguingly, RSPO2 also exerts negative regulatory effects on androgen receptor signaling. Unlike other RSPO family members or canonical Wnt pathway components that may synergize with AR pathways, RSPO2 appears to suppress AR activity, potentially facilitating the emergence of AR-independent prostate cancer clones. This finding is critical because loss of AR reliance is a hallmark of castration-resistant prostate cancer, an incurable stage marked by resistance to standard hormone therapies. Consequently, RSPO2-mediated modulation may underpin this lethal transition, positioning RSPO2 as a unique molecular driver of therapy escape.

At a structural level, bioinformatic modeling using Alphafold2 has demonstrated distinctive three-dimensional conformations of RSPO2 compared to RSPO1, RSPO3, and RSPO4. These structural disparities encompass amino acid sequence variances and hydrophobicity profiles, as well as notable differences in root mean square deviation (RMSD) scoring—parameters vital for protein function and interaction specificity. Such molecular uniqueness intimates that selective pharmacological inhibition of RSPO2 is plausible, a notion of profound therapeutic relevance given the current paucity of targeted Wnt signaling inhibitors effective against RSPO2.

Presently, clinical strategies targeting the Wnt pathway are limited, and there exist no approved agents that selectively inhibit RSPO proteins. The intricate balance of Wnt signaling in normal tissue homeostasis complicates systemic targeting due to potential toxicity. However, the revelation of RSPO2 as a critical, structurally distinct oncogene in metastatic prostate cancer invites the design of novel molecules or biologics aimed precisely at this target, potentially offering a lifeline to patients whose tumors no longer respond to androgen deprivation or chemotherapy.

Furthermore, the study’s integration of genomic data with laboratory models exemplifies a powerful translational approach that bridges molecular discovery with clinical implications. By correlating RSPO2 gene amplifications with phenotypic aggressiveness and demonstrating causal impacts in vitro, the research provides robust evidence to justify pursuing RSPO2 inhibitors in clinical trials. This aligns with a broader oncology movement towards precision medicine, where understanding the unique genetic and proteomic landscapes of tumors informs rational drug development.

The implications of this work extend beyond prostate cancer biology. Given the conserved nature of RSPO proteins within Wnt signaling and the centrality of Wnt dysregulation in numerous malignancies, insights gleaned from RSPO2 could illuminate therapeutic strategies for a broad spectrum of cancers. The concept of exploiting subtle structural differences among highly homologous protein families to selectively target pathological variants could serve as a blueprint for future drug discovery endeavors across oncology.

Moreover, this research challenges existing paradigms by implicating a less-studied member of a gene family as a key driver of cancer aggressiveness and treatment resistance. It underscores the importance of dissecting gene family heterogeneity rather than treating them as functionally redundant units, a principle increasingly supported by advances in structural biology and high-throughput genomics. Such nuances may critically impact patient stratification and biomarker development, fostering the era of individualized cancer therapy.

As metastatic prostate cancer remains a leading cause of cancer-related mortality, especially when hormone therapies fail, the identification of RSPO2 as a molecular culprit opens promising investigative and clinical pathways. Future endeavors will likely focus on refining the biochemical mechanisms of RSPO2, elucidating its interaction networks, and developing selective inhibitors that harness these mechanistic insights. This study represents a significant stride towards transforming aggressive prostate cancer from a terminal diagnosis into a manageable condition through targeted molecular intervention.

In summary, this landmark study not only advances our understanding of the molecular underpinnings of therapy-resistant prostate cancer but also spotlights RSPO2 as a novel and druggable target within the Wnt signaling landscape. The convergence of genomic, biochemical, and structural data charts an exciting course towards next-generation therapeutics capable of overcoming current treatment barriers, heralding hope for millions affected by metastatic prostate cancer worldwide.

Subject of Research:
Advanced prostate cancer; R-spondin family genes; RSPO2 functional role; Wnt signaling pathway in cancer.

Article Title:
Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer

News Publication Date:
25-Jul-2025

Web References:

• Journal: Oncotarget Volume 16
• DOI: 10.18632/oncotarget.28758

Image Credits:
© 2025 Deacon et al. Licensed under Creative Commons Attribution License (CC BY 4.0).

Keywords:
Prostate cancer, RSPO2, R-spondin family, Wnt signaling, epithelial-mesenchymal transition, androgen receptor resistance, gene amplification, structural biology, targeted therapeutics, metastatic cancer.

Prostate cancer, long targeted primarily through therapies aimed at the androgen receptor (AR), often evolves into forms that no longer depend on this signaling pathway, thereby rendering these treatments ineffective. The process of lineage plasticity—where cancer cells alter their identity and become resistant to hormonal therapies—poses a significant clinical challenge. This new research, led by senior author Dr. Joshi J. Alumkal and spearheaded by Zhi Duan, Ph.D., elucidates a molecular driver behind this change, offering hope for patients grappling with aggressive prostate tumors that have outmaneuvered existing treatment modalities.

Their investigation unveiled PROX1 as an early and critical marker in the transformation from androgen receptor-dependent prostate cancer to its more aggressive, androgen receptor-independent subtypes, including double-negative prostate cancer and neuroendocrine prostate cancer. Notably, PROX1 expression was found to increase sharply in tumor cells that lost AR activity, correlating with more aggressive disease phenotypes. By analyzing hundreds of patient tumor biopsies along the lineage plasticity continuum, the researchers established PROX1 not only as a biomarker but as a possible causal agent facilitating the malignant reprogramming of prostate cancer cells.

At a mechanistic level, PROX1 acts as a transcription factor, a protein that binds DNA and controls the expression of other genes, effectively orchestrating the identity and behavior of cancer cells. The study demonstrated an inverse relationship between PROX1 and the androgen receptor across patient tumor datasets, suggesting that PROX1 may actively repress AR expression and function. Experimentally, forcing PROX1 expression in prostate cancer cells resulted in downregulation of AR, reinforcing the idea that PROX1 suppresses AR-driven pathways, fostering cellular plasticity and progression towards treatment-resistant states.

Genetic ablation experiments, which selectively knocked out PROX1 from double-negative and neuroendocrine prostate cancer cells, resulted in significant growth arrest and increased cell death. This evidence firmly supports the notion that PROX1 is not merely a passenger in lineage plasticity but a driver essential for the survival and proliferation of aggressive prostate cancer subtypes. However, the challenge lies in targeting PROX1 pharmacologically, as transcription factors historically have proven difficult to inhibit directly with drugs.

Pivoting around this obstacle, the researchers uncovered a promising indirect strategy by investigating proteins that interact with PROX1. Among these cofactors, histone deacetylases (HDACs) stood out as significant partners. HDACs are enzymes that modify chromatin structure and regulate gene expression and have been successfully targeted in other cancer types with approved inhibitors. Hypothesizing a cooperative relationship, the team tested whether inhibiting HDAC activity could disrupt PROX1 function.

Their results were striking. Treatment of PROX1-expressing prostate cancer cells with HDAC inhibitors led to a notable reduction in PROX1 protein levels, mirroring the effects observed with genetic deletion. As PROX1 diminished, cell viability decreased dramatically, indicating that HDAC inhibitors can thwart the survival mechanisms of these aggressive cancer cells by destabilizing PROX1. Given that HDAC inhibitors are already clinically approved for several cancers, these findings open immediate avenues for repurposing these drugs to combat prostate cancer subtypes prone to lineage plasticity.

This discovery carries profound implications for the future management of prostate cancer. By identifying PROX1 as an early driver of lineage plasticity and establishing a link between PROX1 and HDACs, the study provides a molecular rationale for clinical trials testing HDAC inhibitors in patients with aggressive, androgen receptor-independent prostate cancer. Such trials could herald a new therapeutic frontier for individuals currently facing limited options and poor prognoses.

The research conducted at the University of Michigan Rogel Cancer Center involved a multidisciplinary team of experts spanning molecular biology, oncology, and translational medicine. Utilizing patient-derived tumor biopsies, sophisticated genetic manipulation techniques, and advanced cellular assays, the investigators meticulously mapped PROX1’s role in prostate cancer evolution. Their integrative approach underscores the importance of combining genetic insights with pharmacological innovations to tackle complex, treatment-resistant malignancies.

While the study highlights a promising therapeutic target, further research is necessary to delineate the precise molecular pathways by which PROX1 and HDACs interact and regulate prostate cancer cell fate. It also raises intriguing possibilities about whether similar lineage plasticity mechanisms operate in other cancers, potentially broadening the impact of these findings. Moreover, identifying biomarkers that predict response to HDAC inhibition in prostate cancer patients will be critical for translating these discoveries into clinical benefit.

In addition to advancing fundamental knowledge, this work emphasizes the power of “guilt by association” in drug targeting—leveraging the interactions of untargetable proteins like PROX1 with druggable partners such as HDACs. This conceptual framework could transform how researchers approach other intractable oncogenic drivers in cancer biology, accelerating the development of effective therapies where none currently exist.

As the field anticipates clinical trials informed by this study, patients and clinicians alike have renewed optimism that understanding lineage plasticity at the genetic and epigenetic levels will unlock new keys to controlling and, ultimately, overcoming aggressive prostate cancer. The convergence of molecular biology, genomics, and pharmacology displayed in this research exemplifies the promise of precision medicine in oncology.

This seminal study, entitled “PROX1 is an Early Driver of Lineage Plasticity in Prostate Cancer,” appeared in the Journal of Clinical Investigation and represents a significant stride toward identifying novel intervention points in the fight against one of the most challenging forms of cancer progression. The collaboration between genetic analysis and therapeutic innovation showcased here illustrates how tackling the molecular roots of cancer can translate into tangible clinical advances.

In summary, the identification of PROX1 as a central regulator of prostate cancer lineage plasticity and its functional suppression via HDAC inhibitors heralds an exciting development in cancer research. By potentially repurposing existing drugs to inhibit this newly characterized pathway, the study charts a viable route to counteract treatment-resistant prostate cancer and improve patient outcomes in an area of urgent unmet medical need.

Subject of Research: Cells

Article Title: PROX1 is an early driver of lineage plasticity in prostate cancer

News Publication Date: 2-Jun-2025

References: “PROX1 is an Early Driver of Lineage Plasticity in Prostate Cancer,” Journal of Clinical Investigation

Image Credits: Image courtesy of Michael C. Haffner, M.D., Ph.D., Fred Hutchinson Cancer Center

Keywords: Cancer, Prostate cancer